GleamWall
中文EN

CMND Clearmind Medicine Inc. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1892500 · Fiscal year ends 10/31

Financial factors as of 2026-01-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-33.9%
TTM EPS YoY68.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-119.7%
ROA-74.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets26.1%
Debt / equity0.00x
Current ratio3.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-12.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q1*2026-01-312025Q4*2025-10-312025Q3*2025-07-312025Q2*2025-04-302025Q1*2025-01-312024Q4*2024-10-312024Q3*2024-07-312024Q2*2024-04-30
Income statement
Revenue————————
R&D expense$640,494$420,182$723,048$451,857$461,438$486,491$345,883$322,956
SG&A expense$3.02M$1.04M$684,716$855,124$1.03M$1.10M$1.13M$980,549
Pretax income-$3.85M-$685,648-$1.31M-$763,270-$1.03M-$787,624-$2.05M-$871,461
Income tax$3,960$2,194$8,258$20,658$39,335$97,120$42,590$36,756
Net income-$3.85M-$687,842-$1.31M-$783,928-$1.07M-$884,744-$2.09M-$908,217
EPS (basic)-3.32—-0.25-0.16-9.55—-0.59-0.28
EPS (diluted)-3.32—-0.25-0.16-9.55—-0.59-0.28
Weighted avg. shares (diluted)1.16M—5.34M5.04M112,213—3.56M3.25M
Balance sheet
Cash & equivalents$9.26M$3.92M$3.50M$4.47M$5.78M$6.57M$7.68M$8.31M
Short-term investments$1.09M$1.66M$1,084$177,640$134,723$289,388——
Current assets$11.02M$5.95M$3.82M$5.02M$6.41M$7.09M$7.99M$8.69M
PP&E, netmay include right-of-use assets (IFRS)——————$355$624
Intangibles$94,611$97,372$100,133$102,894$105,565$108,326$111,087$113,848
Total assets$11.14M$6.08M$3.97M$5.18M$6.58M$7.26M$8.17M$8.85M
Current liabilities$2.91M$4.89M$2.90M$2.88M$3.72M$4.13M—$4.20M
Total liabilities$2.91M$4.89M$2.90M$2.88M$3.73M$4.15M$4.70M$4.20M
Shareholders' equity$8.24M$1.19M$1.07M$2.30M$2.85M$3.11M$3.47M$4.65M
Cash flow statement
Operating cash flow-$2.08M-$1.29M-$1.08M-$1.10M-$1.27M-$1.08M-$1.13M-$1.19M
Investing cash flow—-$524,433$112,954-$200,000$69,462-$350,400$33,803—
Financing cash flow$7.42M$2.24M-$10,812-$10,298$404,812$323,205$469,537$145,129
Stock-based compensation$1.41M$115,640$77,790$231,722$380,738$182,498$377,279$290,091

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.